Business Description
![Syntara Ltd Syntara Ltd logo](https://static.gurufocus.com/logos/0C00000C82.png?14)
Syntara Ltd
NAICS : 325412
SIC : 2834
ISIN : AU0000312480
Description
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 12.57 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -22.61 | |||||
Beneish M-Score | -5.43 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.6 | |||||
3-Year EBITDA Growth Rate | 32.7 | |||||
3-Year EPS without NRI Growth Rate | 21.4 | |||||
3-Year FCF Growth Rate | 32 | |||||
3-Year Book Growth Rate | 48.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 58.83 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 70.34 | |||||
9-Day RSI | 60.77 | |||||
14-Day RSI | 56.52 | |||||
6-1 Month Momentum % | 73.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.75 | |||||
Quick Ratio | 1.75 | |||||
Cash Ratio | 0.77 | |||||
Days Inventory | 435.01 | |||||
Days Sales Outstanding | 266.89 | |||||
Days Payable | 632.61 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.1 | |||||
Shareholder Yield % | -1.53 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 61.55 | |||||
Operating Margin % | -458.85 | |||||
Net Margin % | -277.28 | |||||
FCF Margin % | -248.71 | |||||
ROE % | -118.54 | |||||
ROA % | -54.45 | |||||
ROIC % | -236.13 | |||||
ROC (Joel Greenblatt) % | -489.15 | |||||
ROCE % | -91.73 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.83 | |||||
PB Ratio | 4.38 | |||||
Price-to-Tangible-Book | 3.5 | |||||
EV-to-EBIT | -2.89 | |||||
EV-to-EBITDA | -3.02 | |||||
EV-to-Revenue | 8.9 | |||||
EV-to-Forward-Revenue | 2.15 | |||||
EV-to-FCF | -3.23 | |||||
Price-to-Median-PS-Value | 0.58 | |||||
Price-to-Net-Current-Asset-Value | 3.5 | |||||
Earnings Yield (Greenblatt) % | -34.6 | |||||
FCF Yield % | -24.7 |